153 8 DELIRIUM | PART THREE 37. Aapro M, Molassiotis A, Dicato M et al; PEER investigators. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012;23:198692. 38. Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-42. 39. Szturz P, Wouters K, Kiyota N et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced nonnasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 2017;22:105666. 40. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and metaanalysis. Kidney Int 2012;81:442-8. 41. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-70. 42. Lassnigg A, Schmidlin D, Mouhieddine M et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004;15:1597-605. 43. Hoste EA, Kellum JA. Acute renal failure in the critically ill: impact on morbidity and mortality. Contrib Nephrol 2004;144:1-11. 44. Celio L, Frustaci S, Denaro A et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011;19:1217-25. 45. Kaushal J, Gupta MC, Kaushal V et al. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singap Med J 2010;51:871-5. 46. Tian W, Wang Z, Zhou J et al. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapyinduced nausea and vomiting in a Chinese population. Med Oncol 2011;28:71-8. 47. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010;18:423-31. 48. Hesketh PJ, Wright O, Rosati G et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 2012;20:147178. 49. Tanioka M, Kitao A, Matsumoto K et al. A randomised, placebo-controlled, doubleblind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013;109:859-65. 50. Gralla R, Bosnjak S, Hontsa A et al. A phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25:1333-9.
RkJQdWJsaXNoZXIy MjY0ODMw